source
- Freenome's updated blood test shows stronger detection of precancerous lesions, boosting Abbott's market prospectsFreenome announced that its revised SimpleScreen CRC blood test met both primary and secondary goals in a pivotal validation study. The new data indicate better performance than the earlier version…
- Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cove…BioPharma Dive · 1mo agoPositive readoutPositive